405
Participants
Start Date
January 25, 1994
Primary Completion Date
August 15, 2011
Study Completion Date
January 6, 2012
bleomycin sulfate
10 units/m2
dacarbazine
375mg/m2
doxorubicin hydrochloride
25mg/m2
vinblastine
6mg/m2
radiation therapy
35Gy in 20 fractions (daily)
Instituto del Radio O. Alberti Spedali Civili, Brescia
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Vancouver Island Cancer Centre, Victoria
The Vitalite Health Network - Dr. Leon Richard, Moncton
Regional Health Authority B, Zone 2, Saint John
Dr. H. Bliss Murphy Cancer Centre, St. John's
QEII Health Sciences Centre, Halifax
Health Sciences North, Greater Sudbury
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Trillium Health Partners - Credit Valley Hospital, Mississauga
Stronach Regional Health Centre at Southlake, Newmarket
Lakeridge Health Oshawa, Oshawa
Algoma District Cancer Program, Sault Ste. Marie
Humber River Hospital, Toronto
Sinai Health System, Toronto
University Health Network, Toronto
CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Policlinico Monteluce/Univ. Degli Studi Di Perugia, Perugia
Royal South Hants Hospital, Southampton
Lead Sponsor
Eastern Cooperative Oncology Group
NETWORK
NCIC Clinical Trials Group
NETWORK